International Kidney Cancer Symposium (IKCS) 2021
The International Kidney Cancer Symposium (IKCS) 2021 took place in [...]
Immune cell patterns can help predict if kidney cancer patients will respond to immunotherapy
In a study published in Cancer Cell last week, researchers [...]
PARP1 as a potential biomarker for response to immunotherapy
In a recent study, the researchers looked at the RNA [...]
SMC approves cabozantinib/nivolumab combination for advanced kidney cancer in Scotland
The Scottish Medicines Consortium (SMC) has approved the use of [...]
ESMO 2021: Sarcomatoid and/or rhabdoid RCC treated with immune checkpoint inhibitors after surgery
Cytoreductive nephrectomy is the surgical removal of the tumour to reduce the number [...]
Outcomes and side effects after first-line treatment with combination therapies for kidney cancer
This report looked at the results from 4 studies comparing [...]
ESMO 2021: Pembrolizumab as monotherapy for first-line treatment of non-clear cell kidney cancer
Non-clear cell RCC is about 20-25% of all RCC diagnoses [...]
ESMO 2021: Pembrolizumab as monotherapy for first-line treatment of kidney cancer
KEYNOTE-427 is an open-label, single-arm, phase II study to look [...]
Camrelizumab plus famitinib in patients with advanced or metastatic kidney cancer
An ongoing phase 2 study of a combination of two [...]
Immunotherapy and COVID-19 in cancer patients
A recent review published in the Journal for ImmunoTherapy of [...]
